拥挤药物类别中的药物审批可能反映疗效高估和假阳性:免疫检查点抑制剂试验的组合分析
该研究对免疫检查点抑制剂(ICI)的111项试验进行组合分析,采用Stein估计和多重性校正重新计算关键试验的效应量与P值。结果显示,35%的关键试验效应量在校正后出现有意义减弱,27%的显著P值失去显著性,提示药物审批与报销决策中的疗效估计可能存在误差。
要点
- 对ICI试验进行统计校正后,35%的关键试验疗效估计出现有意义减弱。
- 在74项P值显著的试验中,27%经多重性校正后失去显著性。
- 药物审批与报销决策需考虑整个药物类别的随机误差。
核心结论
- 对ICI试验总体进行统计校正后,关键试验的效应量普遍减小,部分P值失去显著性。
研究设计与样本
- 从ClinicalTrials.gov下载ICI试验注册信息,纳入以OS或PFS为主要结局、1-3期、样本量≥100、至少一个美国站点、主要完成日期在2023年1月1日前的试验,共纳入14种ICI的111项试验。
主要发现
- 在FDA批准的药物中,82个作为主要结局支持审批的OS/PFS风险比被重新计算,其中1个(1%)估计有意义改善,29个(35%)有意义减弱。
- 74个(90%)OS/PFS风险比的原始P值小于0.05,其中20个(27%)校正后P值失去显著性。
关键数值与推荐
- 效应量变化定义为校正后风险比跨越无效线或跨越ESMO-MCBS截断值。
临床怎么用
- 在药物审批、报销及临床决策中,应关注整个药物类别的试验数据并进行统计校正以减少误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Institutions making decisions regarding drug development, approval, or insurance reimbursement require accurate estimates of drug efficacy that reflect the drug's true value. Stein estimation and multiplicity correction can be applied to trials for an entire class of drugs, minimizing random error in effect size estimates. STUDY DESIGN AND SETTING: We downloaded ClinicalTrials.gov registry entries for trials testing immune checkpoint inhibitor (ICI) drugs, including only trials with overall survival (OS) or progression-free survival (PFS) as a primary outcome, in phases 1-3, with 100 patients or more, at least one US site and primary completion date before January 1, 2023. Effect sizes and P values were recalculated for pivotal trials. A change was considered "meaningful" if the adjusted hazard ratio (HR) crossed the null or an European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Score (MCBS) cutoff. RESULTS: We included 14 ICIs, eight of which were approved by the Food and Drug Administration (FDA). These were tested in 111 trials, 45 of which led to FDA approvals. Among FDA-approved drugs, 82 distinct OS/PFS HRs were reported as primary outcomes supporting an FDA label approval/revision. After recalculation, estimates improved to a meaningful degree for one pivotal trial (1%) but diminished meaningfully for 29 (35%). Among OS/PFS HRs, 74 (90%) had an original P value that was less than 0.05. Among these, 20 (27%) had a corrected P value that lost significance. CONCLUSION: When statistically adjusting for the totality of trials testing ICIs, effect sizes in pivotal trials generally decreased, and some P values lost significance. This may have implications for minimizing error in approval, reimbursement, and certain clinical decisions. PLAIN LANGUAGE SUMMARY: Drug approval and insurance reimbursement require accurate estimates of drug efficacy. In cases where drugs are tested in many different trials, statistical methods can be used to minimize error among efficacy estimates. In this paper, we use a statistical method to minimize error in calculations of the efficacy of drugs in a class of cancer drugs known as "immune checkpoint inhibitors" (ICIs). After this adjustment, there was a meaningful improvement in the estimate of efficacy for one (1%) of the clinical trials of ICIs that were used to justify FDA approvals, but estimates of efficacy for 29 (35%) of pivotal trials meaningfully worsened. We also corrected for potential false positives among trials in our sample. Among the 74 (90%) drug trials that had a significant result (P < .05), 20 (27%) lost significance after correction. The analyses performed herein have potential for reducing the potential bias in efficacy estimates used for making policy.
引用
- Carlisle BG, Gönen M, Fernandez L, et al. Drug approvals in crowded drug classes potentially reflect efficacy overestimates and false positivity: A portfolio analysis of immune checkpoint inhibitor trials. J Clin Epidemiol. 2026. PMID: 41692173. doi:10.1016/j.jclinepi.2026.112182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。